A gene editing platform developed by Cellectis called TALEN was able to restore healthy hemoglobin production in preclinical models of…
Articles by Marisa Wexler, MS
Forma Therapeutics, which is currently developing an experimental treatment for sickle cell disease (SCD) called etavopivat, is being…
The National Institutes of Health (NIH) has awarded a five-year, $7.7-million grant to support a new research project that seeks…
People with sickle cell anemia (SCA) — the most common and the most severe form of sickle cell disease…
Intravenous bisphosphonate therapy can ease bone pain in children with sickle cell disease (SCD), a new study reports. The…
Children with sickle cell disease (SCD) exposed to higher doses of the oral therapy hydroxyurea report better blood-related…
The gene editing therapy EDIT-301 appears to be working as intended in the first person with sickle cell disease…
Note: This story has been updated July 19, 2022, to correct that voxelotor is approved in the U.S.
Two mouse models commonly used to study sickle cell disease (SCD) are not suitable for testing certain gene editing…
A novel strategy called Engineered Stem Cell Antibody Paired Evasion (ESCAPE) could be used to more safely prepare people with…